Floatz logo

Pertuzumab

Tumor Of Salivary Gland

Cancer Research UKmonoclonal_antibodyPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Tumor Of Salivary Gland cohort.

Asset / SponsorPhaseRating
Trastuzumab
Cancer Research UK
Phase 2/3B
Alectinib
Hoffmann-La Roche
Phase 2CCC
Anti-Her2 Antibody-Drug Conjugate A166
Klus Pharma Inc.
Phase 1/2CCC
Ava-6000 (Fap-Activated Doxorubicin Prodrug)
Avacta Life Sciences Ltd
Phase 1CC
Rimiducid
Poseida Therapeutics, Inc.
Phase 1CC
P-Psma-101 Car-T Cells
Poseida Therapeutics, Inc.
Phase 1CC

Same molecule, other indications

Pertuzumab is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 3
75 / 100
View asset →
inflammatory breast carcinomaActive
BBB
Indicative · Phase 3
72 / 100
View asset →
breast cancerActive
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →